| __timestamp | Amicus Therapeutics, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 17763000 |
| Thursday, January 1, 2015 | 47269000 | 22180000 |
| Friday, January 1, 2016 | 71151000 | 37257000 |
| Sunday, January 1, 2017 | 88671000 | 27367000 |
| Monday, January 1, 2018 | 127200000 | 64770000 |
| Tuesday, January 1, 2019 | 169861000 | 74986000 |
| Wednesday, January 1, 2020 | 156407000 | 79256000 |
| Friday, January 1, 2021 | 192710000 | 100156000 |
| Saturday, January 1, 2022 | 213041000 | 131408000 |
| Sunday, January 1, 2023 | 275270000 | 152946000 |
Unleashing the power of data
In the competitive world of biotechnology, managing operational expenses is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Amicus Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Amicus Therapeutics has seen a significant increase in SG&A expenses, growing by approximately 1,230%, from $20.7 million in 2014 to $275.3 million in 2023. In contrast, Dynavax Technologies Corporation's SG&A expenses rose by about 760%, from $17.8 million to $152.9 million. This disparity highlights Amicus's aggressive expansion strategy, potentially reflecting its investment in market penetration and operational scaling. Meanwhile, Dynavax's more conservative growth in expenses suggests a focus on optimizing existing operations. Understanding these trends provides valuable insights into each company's strategic priorities and financial health, offering a window into their future trajectories.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
CymaBay Therapeutics, Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs MannKind Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation